When a scientist at pharmceutical company Chemacran dies suddenly after promising him a big story, Terry begins investigating the company's antidepressant, Seraban, whose success has led to a forthcoming lucrative merger, while Maureen tries to get the scoop on J.P. O'Farrell, Chemacran's managing director.